ProShares, the Bethesda-based ETF provider who launched the first bitcoin-linked ETF in the United States last year, has announce the opening of its new headquarters at The Wilson on Wisconsin Avenue in Bethesda, a sign of the fast-growing asset management firm’s commitment to the Greater Washington D.C. area.

ProShares has more than doubled in size over the past three years to over $70 billion under management, while launching innovative products like BITO, the first-ever bitcoin-linked ETF in the United States, and VERS, a new thematic ETF that allows investors to access the companies shaping the metaverse. The firm has grown to more than 160 employees, most of whom will work out of its new downtown headquarters.


Early data from landmark study shows rapid whole genome sequencing (rWGS) provided diagnostic insights for more than half of newborns who received testing; one-third had no previously documented clinical suspicion of a genetic condition

GeneDx, LLC, is a global leader in genomics headquartered in Gaithersburg, providing testing to patients and their families worldwide. Originally founded by scientists from the National Institutes of Health, GeneDx offers a world-renowned clinical genomics program with particular expertise in rare and ultra-rare genetic disorders.


Curiosity Stream is a Silver Spring-based media company and subscription video streaming service that offers documentary programming including films, series, and TV shows. It was launched in 2015 by the founder of the Discovery Channel, John S. Hendricks

“We are thrilled to announce that we exceeded our revenue target for the second year in a row, exceeding $71 million in 2021 as our investments in content, people, and technology continued to bear fruit,” said Clint Stinchcomb, President & CEO. “Over the past year, we have more than doubled the size of our content library, and our 2022 content slate promises to be our biggest and best yet. Later this year, we plan to better align the value we bring to our subscribers with new subscription plan pricing. As a mission-driven company, we are relentlessly focused on satisfying humanity’s enduring curiosity about our world. Looking ahead to the remainder of 2022 and beyond, we are excited to fulfill our mission by delivering premium factual content that informs, enchants, and inspires.”


QIAGEN, a Netherlands-based holding company with its U.S. headquarters in Germantown, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life.

Used to test patients in over 130 countries, the fourth generation QuantiFERON®-TB Gold Plus assay identifies interferon-gamma released by T-cells following recognition of TB specific antigens as a marker of TB infection. Interferon gamma release assays (IGRA) require only one patient visit to a healthcare provider and are more accurate than the traditional two-visit skin test that has been used for over a century to detect the latent form of the infection.


Per the City of Takoma Park:

The City of Takoma Park is awarding grant funds to support local small businesses in the City. The Department of Housing & Community Development is releasing these funds as a grant to eligible small businesses. The full grant application can be found here:


Southern Management Cos has written a letter to Montgomery County Executive Marc Elrich and the County Council, on behalf of 48 Montgomery County Apartment communities and 14 multi-family owner/developers/managers, expressing their concern with the rent hike cap, citing various reasons.

The full letter can be seen below.


Rockville-based Emmes (401 N Washington Street), a global, full-service Clinical Research Organization (CRO) dedicated to supporting the advancement of public health and biopharmaceutical innovation, last week announced that it has acquired Casimir, a U.S.-based CRO. Casimir has experience in more than 20 rare diseases and has worked with regulators, sponsors and patients to develop outcome measures that capture the nuances of disease progression and treatment benefit.

Emmes Chief Executive Officer Dr. Christine Dingivan said, “This is the fourth acquisition for Emmes in just over a year, as we continue to add new biopharma clients and deepen our innovative research capabilities. The combination of Casimir and Emmes will further differentiate our global rare disease center of excellence, Orphan Reach™. We plan to continue and accelerate the groundbreaking work of Casimir in neurodegenerative and neuromuscular conditions with remote data capture and patient outcome standardization.”


Reports Promising Early Data from Lead Clinical Program, JK07, for the Treatment of Heart Failure with Reduced Ejection Fraction 

Initiates Enrollment in Second Cohort of JK07 Phase 1 Dose Escalation Study


View More Stories